A medical device for the selective dissection of pathological tissues and fibrosis

ended

Surgery is the art of dissecting tissues in order to repair, remove, or replace a diseased or damaged organ. 30% of the global burden of disease can be attributed to surgically treatable conditions. More than 10% of surgical procedures involve critical dissection steps whereby the pathological tissue is carefully separated from the healthy surrounding tissues. These procedures together have an incidence of 150/100.000 people, amounting for 2 million surgeries per year in developed countries. Despite the importance of selective dissection in surgical procedures, the current tools are sub-optimal because they are all still relying either on tearing force or on non-selective cutting that can damage tissues. Auxin Surgery, a pioneer in novel dissection methods, has found a revolutionary system, CADISS, that combines mechanical force with the topical application of a chemical drug, Mesna that weakens adhesion between tissues thereby facilitating the dissection steps and minimizing the damages to health tissues. CADISS saves time, therefore patients need to undergo anesthesia for shorter period, thereby reducing the risks of complications. Moreover, hospitals save money on the usage of operating rooms and hospital personnel and can optimize the occupation of hospital space. The global general surgery devices market size was valued at over €10 billion in 2016 and is expected to grow at a CAGR of 8.5% by 2025. Chemically assisted dissection can be useful in most surgical procedures consisting in separation of two tissues along a cleavage plane and when at least one of these conditions is true: 1) the risk of relapse is present 2) the risk of side-effects through damage of healthy tissue is present or 3) the risk of facing difficulties for the surgeon is present. CADISS will bring our company to international expansion and growth reaching €23.9M in revenues 3 years after market launch.